1. Home
  2. FEMY vs RADX Comparison

FEMY vs RADX Comparison

Compare FEMY & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEMY
  • RADX
  • Stock Information
  • Founded
  • FEMY 2004
  • RADX 2021
  • Country
  • FEMY United States
  • RADX Australia
  • Employees
  • FEMY N/A
  • RADX N/A
  • Industry
  • FEMY Medical/Dental Instruments
  • RADX
  • Sector
  • FEMY Health Care
  • RADX
  • Exchange
  • FEMY Nasdaq
  • RADX NYSE
  • Market Cap
  • FEMY 29.9M
  • RADX 32.5M
  • IPO Year
  • FEMY 2021
  • RADX N/A
  • Fundamental
  • Price
  • FEMY $0.83
  • RADX $4.64
  • Analyst Decision
  • FEMY Strong Buy
  • RADX Strong Buy
  • Analyst Count
  • FEMY 3
  • RADX 3
  • Target Price
  • FEMY $8.67
  • RADX $15.00
  • AVG Volume (30 Days)
  • FEMY 158.0K
  • RADX 18.6K
  • Earning Date
  • FEMY 08-07-2025
  • RADX 02-26-2025
  • Dividend Yield
  • FEMY N/A
  • RADX N/A
  • EPS Growth
  • FEMY N/A
  • RADX N/A
  • EPS
  • FEMY N/A
  • RADX N/A
  • Revenue
  • FEMY $1,699,232.00
  • RADX $204,609.00
  • Revenue This Year
  • FEMY $283.83
  • RADX N/A
  • Revenue Next Year
  • FEMY $161.03
  • RADX N/A
  • P/E Ratio
  • FEMY N/A
  • RADX N/A
  • Revenue Growth
  • FEMY 61.97
  • RADX N/A
  • 52 Week Low
  • FEMY $0.69
  • RADX $3.50
  • 52 Week High
  • FEMY $1.80
  • RADX $50.82
  • Technical
  • Relative Strength Index (RSI)
  • FEMY 37.62
  • RADX N/A
  • Support Level
  • FEMY $0.91
  • RADX N/A
  • Resistance Level
  • FEMY $0.93
  • RADX N/A
  • Average True Range (ATR)
  • FEMY 0.04
  • RADX 0.00
  • MACD
  • FEMY -0.01
  • RADX 0.00
  • Stochastic Oscillator
  • FEMY 5.12
  • RADX 0.00

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD

Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Share on Social Networks: